The global cell culture market size was estimated at USD 16.4 billion in 2019. Development of novel three-dimensional cell culture techniques and growing need for these techniques for biopharmaceutical development and vaccine production are expected to drive demand and growth in revenue.
Growing advancement of proteomic gene expression and consequent development of novel vaccine and biopharmaceuticals is anticipated to drive demand for newer 3D cell culturing techniques and cell cultures over the forecast period. Further increase in the number of cancer research projects and enhanced applications of gene therapies are also factors expected to drive the demand in this market over the forecast period.
Owing to the cost and investment involved in setting up cell culture technology infrastructure, the number of contract research and manufacturing is increasing. Increasing incidences of chronic diseases have led to increase in cell biology & cytological studies and associated research resulting in the growth for cell culture. The stem cell therapy research is at its peak in order to treat the cause of the disease supported by huge funding for the same.
The limited applicability of conventional pharmaceuticals and few numbers of players in the biotechnology industry has fueled the growth of cell culture technology. The market for these artificial organs is expected to grow at a significantly high growth rate in the near future, indicating an increasing demand and strong growth potential for the cell culture market.
Development of specialty growth media and culture techniques that ensure specificity and availability of high-end technology for scaling up cultures are important factors that are expected to drive growth in these market segments.
With the advancement of cell culture technology, the distinction between pharmaceuticals and biotechnology is fading. In order to extend their product portfolios and boost their market position, many pharmaceutical corporations are purchasing or merging with biotechnology enterprises. Cell culture technology is in high demand among academics, researchers, and bioprocessing and manufacturing labs. The number of contract research and manufacturing companies is growing as a result of the high cost and investment required to build up cell culture technological infrastructure.
Advances in proteomic gene expression and the development of innovative vaccines and biopharmaceuticals are projected to drive demand for novel cell cultures, and 3D cell culture techniques. Over the forecast period, increased applications of gene therapy and an increasing number of cancer research projects are likely to increase cell culture market growth.
Furthermore, as the number of chronic diseases is rising, a number of cell biology and cytological investigations, as well as related research, results in an increase in usage of cell culture. For instance, according to World Health Organization statistics, in 2021, globally 41 million deaths occur due to chronic diseases. The most common chronic disease is cardiovascular disease it kills 17.9 million people per year, followed by cancer (9.3 million), respiratory disorders (4.1 million), and diabetes (1.5 million). Such high numbers of deaths by chronic diseases is forcing the market leaders to improve and innovate the biologics product.
Biopharmaceuticals consist of drugs of microbiological origin such as hormones, vaccines, monoclonal antibodies, therapeutic enzymes, blood factors, etc. High specificity of biopharmaceuticals has opened up new avenues in healthcare such as personalized medicine, wherein various diseases or conditions can be treated using specific biomolecules depending upon the patient’s physiological, biological, and genetic makeup. Limited applicability of conventional pharmaceuticals and relatively lesser numbers of players in the biotechnology industry have fueled the growth of cell culture technology.
The process of cell culture is characterized by the presence of a number of stages which are strictly monitored for various parameters including temperature, humidity, nutrients, surface area, aeration, toxins and contamination. The technique requires precise handling of all the components since any deviations will have a direct effect on the efficacy of the final product that may be a cell line, tissue, organ or biomolecules. This calls for use of strict control systems, which add up to the total cost of development and manufacturing. Such constraints may lead to a bottleneck in the progress and development of cell culture techniques, thereby restraining market growth.
Cell culture processes use serum from various sources, the most common being bovine fetus. According to an article published in The Biomedical Scientist, every year over two million bovine fetuses are subjected to intense suffering caused by the inhuman process of blood collection from the fetus’s heart, without anesthesia. The issue has become a matter of utmost concern for scientists and manufacturers, which is expected to have a restraining effect on the growth of the overall cell culture market. Owing to the increasing awareness, the government is taking stringent actions and implementing regulations to control the use of living origin.
Based on consumables, the market is segmented into cell culture media, sera, and reagent. The highest growth among these segments is being observed in the media market. The cell culture market is driven by increasing vertical integration, growth of the biopharmaceutical industry owing to increasing demand and preference for alternative media.
Cell culture media forms the largest share by volume for any culture preparation. However, as compared to average market prices of sera and reagents, media is very lower-priced, and thus even though having a higher volume consumption accounts for a smaller share of the revenue. Growing demand for culturing in cytological research projects, it is expected that the segment will witness considerable demand over the forecast period.
Cell culture products are characterized by higher profit margins and technological advancements are key for the growth of these segments. The primary clients are research laboratories and cell culture application development companies. Major segments included are culture systems, incubators, centrifuges, cryostorage equipment, biosafety equipment, and pipetting instruments.
Cell culture systems account for the largest share of this market due to the introduction of technological advancements in operation and design of these systems for researchers and laboratories. The development of automated robotic liquid handling systems is expected to enhance culture capacity and maintenance of high levels of purity in a reproducible manner.
Biopharmaceuticals were observed to account for the largest share of revenue for 2014 in the applications of cell culture techniques. Due to the primary usage of mammalian cell cultures in the production of mammalian pharmaceuticals and the growing demand for non-conventional drugs developed as a result of bio-production of proteomically and genetically enhanced drugs, this segment is expected witness lucrative growth in demand over the forecast period.
With the advancement in technologies to develop and culture tissue from cells for use in grafting and techniques of personalized genomic and proteomic surgical therapies, growth in demand for these techniques is also expected to significantly drive demand for cell culturing over the forecast period.
North America dominated the cell culture market and accounted for the largest revenue share of 40.39% in 2021. North America continues to focus on innovating cell culture applications, and instrumentation. Besides, with an increased preference for the use of animal component-free media, the market is likely to experience more investments in the media market to support the overall cell culture industry. Moreover, technological innovation in the area of cell culture instruments and equipment has also resulted in significant growth in this region.
The U.S. healthcare and life science industry are early adopters of cell culture techniques, which has led to the high market share of this country. One of the key driving factors of the U.S. cell culture market is the ongoing research and expansion of the biopharmaceutical sector in the country. Currently, a high number of biotherapeutics are in the clinical development phase and are being produced using various cell lines, such as mammalian and transgenic. This expansion drives the demand for, and development of, novel solutions to meet the growing demand of local consumers. For Instance, in January 2022, Mammoth Biosciences signed a collaborative agreement with German company Bayer, to develop in vivo gene editing therapies using Mammoth’s CRISPR system. Such collaborative initiatives are driving the market.
Germany holds a significant share in stem cell research for regenerative medicine and is expected to dominate the cell culture market along with other European nations, such as France and UK. The high volume of cell culture research in the field of oncology and stem cells drives growth of overall cell culture market in Germany. The improving techniques and equipment for cell culture testing also aid in growth of this market. For instance, in February 2022, Medigene and BioNTech collaborated to develop TCR-based immunotherapy to inhibit cancer. This collaboration is for next 3 years. Such collaborations for advancements are driving the market in Germany. However, ethical issues related to embryonic stem cell research along with growing trend of outsourcing clinical research to developing countries are expected to limit the demand and adoption in the country.
Continuous advancements, development of regenerative medicines with growing cases of genetic and chronic diseases are driving the cell culture market in India. due to the presence of high unmet medical demands in India's emerging economy, as well as quickly rising healthcare R&D investment and rising medical expenditures. Government initiatives to be with growing drug development trends in the industry play a big role to drive the market. For instance, In January 2022, The Union health ministry of India amended the New Drugs & Clinical Trials to add cell culture-derived products into the new definition of new drugs with stem cell products. Such government initiatives are expected to drive the market further.
Key participants of the cell culture market include Sigma-Aldrich Co., LLC, Sartorius, Thermo Fisher Scientific, Becton, Dickinson & Company, General Electric, Lonza, Corning, Merck, Promocell, and Eppendorf.
Many pharmaceutical companies are acquiring or merging with biotechnological companies in order to expand their product portfolios and strengthen their market position.
Base year for estimation
2014 - 2018
2020 - 2022
Revenue in USD million/billion and CAGR from 2020 to 2022
Revenue forecast, company ranking, competitive landscape, growth factors, and trends
Consumables, products, application, and region
North America; Europe; Asia Pacific; Latin America; Middle East & Africa
U.S., Canada, Germany, UK, China, Japan, Brazil, South Africa
Key companies profiled
Sigma - Aldrich Corporation; Thermo Fisher Scientific, Inc; Becton, Dickinson and Company; Merck KGAA; Sartorius AG; VWR International, LLC; Eppendorf AG; Promocell GmbH; EMD Millipore; Biospherix
Free report customization (equivalent to up to 8 analyst working days) with purchase. Addition or alteration to country; regional, and segment scope.
Pricing and purchase options
Avail customized purchase options to meet your exact research needs. Explore purchase options
This report forecasts revenue growth at global, regional & country levels and provides an analysis of the industry trends in each of the sub-segments from 2012 to 2022. For the purpose of this study, Grand View Research has segmented the global cell culture market report on the basis of consumables, products, application, and region:
Consumable Outlook (Revenue, USD Million, 2012 - 2022)
Minimum Essential Media (MEM)
RPMI 1640 Media
F-10 Serum Free Media
Fetal Bovine Serum
Other Animals’ serum
Product Outlook (Revenue, USD Million, 2012 - 2022)
Application Outlook (Revenue, USD Million, 2012 - 2022)
Tissue Culture & Engineering
Regional Outlook (Revenue, USD Million, 2012 - 2022)
Middle East & Africa
b. According to the study by Grand View Research, the market size of global cell culture market is projected to reach USD 37.0 billion by 2022.
b. North America accounted for the largest cell culture market share in 2014.
b. Key participants include Sigma-Aldrich Co., LLC, Sartorius, Thermo Fisher Scientific, Becton, Dickinson & Company, General Electric, Lonza, Corning, Merck, Promocell, and Eppendorf.
b. Asia Pacific region is anticipated to grow during the forecast period owing to the presence of high unmet need for increasing production and development of vaccines, drugs, and new biologics.
b. The key players are involved in extensive R&D of 3D cell culture and full commercialization of the technologically advanced cell culture which offer higher accuracy of replication, greater purity and rapid growth.
NEED A CUSTOM REPORT?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.
Contact us now to get our best pricing.
We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure.
"The quality of research they have done for us has been excellent."
Biopharmaceutical innovators are at the forefront of the human response to the coronavirus pandemic. A significant number of major biotech firms are in the midst of a race to investigate the Sars-Cov-2 genome and prepare a viable vaccine for the same. As compared to the speed of response to SARS/MERs etc, the biotech entities are investigating SARs-Cov-2 at an unprecedented rate and a considerable amount of funds are being put into the R&D. With multiple candidates in trial, the public and private sectors are anticipated to work in unison for the foreseeable period, until a vaccine is developed for Covid-19. The report will account for Covid19 as a key market contributor.